Substituted Heterocyclic Compounds for Selective Kinase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for metastatic disease, are often palliative and lack long-term curative options, and there is a need for new drugs effective in monotherapy or combination therapies to address resistant tumors due to the heterogeneity of cancer cells and the complexity of cellular signaling pathways involved in cancer development.
Innovation Solution
Development of substituted heterocyclic and tetrahydroisoquinoline compounds that target specific molecular mechanisms, such as the RET and EphA8 pathways, to selectively induce cell death in cancer cells, thereby treating cancer and cell proliferative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current drug therapies are used for metastatic cancer, then palliative treatment is provided, but long-term cure is seldom achieved
Solution Approach 1:
The patent modifies the chemical structure of known kinase inhibitors by introducing specific substituted heterocyclic groups at defined positions, thereby changing the molecular parameters to achieve enhanced potency and selectivity against cancer cell kinases, transforming palliative agents into potentially curative therapies
Solution Approach 2:
The invention combines multiple functional moieties into a single molecular entity - a core heterocyclic structure with specific substituents including aryl, heteroaryl, or alkyl groups - creating a composite molecular architecture that targets multiple cellular pathways simultaneously, improving curative effectiveness
2Adaptability or versatility
If new chemotherapies are developed to address cancer heterogeneity, then treatment options increase, but prediction of cancer response becomes more difficult
Solution Approach 1:
The patent divides the complex problem of cancer heterogeneity into targetable segments by identifying and inhibiting specific kinase enzymes (such as Src, Tec, EphA8, and RET) that drive different cancer pathways, allowing for tailored treatment approaches based on the specific molecular profile of each tumor
Solution Approach 2:
The substituted heterocyclic compounds serve as molecular intermediaries that bridge the gap between diverse cancer mutations and a common therapeutic mechanism - kinase inhibition - providing a predictable treatment approach that works across different cancer types by targeting the shared downstream signaling pathways
3Productivity
If receptor tyrosine kinases are dysregulated leading to uncontrolled cell growth, then cancer develops, but selective targeting of cancer cells becomes necessary to avoid harming normal cells
Solution Approach 1:
The patent introduces specific local modifications to the kinase inhibitor structure - particular substituted heterocyclic groups at defined positions - that enhance the drug's affinity and selectivity for cancer-associated kinase variants while maintaining lower affinity for kinases in normal cells, thereby achieving selective targeting
Solution Approach 2:
Instead of attempting to stimulate normal cell function, the patent inverts the approach by selectively inhibiting the dysregulated kinase activity in cancer cells - targeting the pathological state rather than the physiological state - thereby achieving cancer cell selectivity while sparing normal cells
Data Source
AI summary
The present invention relates to substituted heterocyclic compounds and substituted tetrahydroisoquinoline compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted benzodiazepine compounds and substituted tetrahydroisoquinoline compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical compositions to subjects in need thereof.